Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease

Therapeutic Advances in Respiratory Disease

Volumn 5, Issue 5, 2011, Pages 345-357

  Vogelmeier, Claus ^a   Magnussen, Helgo ^b   Laforce, Craig ^c   Owen, Roger ^d   Kramer, Benjamin ^e  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b KRANKENHAUS GROSSHANSDORF   (Germany)

^c North Carolina Clinical Research   (United States)

^d NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

24 hour bronchodilation; chronic obstructive pulmonary disease (COPD); indacaterol; long acting 2 agonist (LABA); once daily dosing

Indexed keywords

CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; INDACATEROL; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE;

BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; EVENING DOSAGE; FORCED EXPIRATORY VOLUME; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; INSPIRATORY CAPACITY; LONG TERM CARE; META ANALYSIS; MORNING DOSAGE; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHODILATOR AGENTS; DELAYED-ACTION PREPARATIONS; FORCED EXPIRATORY VOLUME; HUMANS; INDANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; TIME FACTORS;

EID: 80052609149     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465811410100     Document Type: Review

References (29)

1. Balint B. Watz H. Amos C. Owen R. Higgins M. Kramer B. INSURE Study Investigators (2010) Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone. Int J Chron Obstruct Pulmon Dis 5: 311–318.
2. Barnes P.J. Pocock S.J. Magnussen H. Iqbal A. Kramer B. Higgins M. (2010) Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther 23: 165–171.
3. Belman M.J. Botnick W.C. Shin J.W. (1996) Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 153: 967–975.
4. Bourbeau J. Bartlett S.J. (2008) Patient adherence in COPD. Thorax 63: 831–838.
5. Boyd G. Morice A.H. Pounsford J.C. Siebert M. Peslis N. Crawford C. (1997) An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 10: 815–821.
6. Breekveldt-Postma N.S. Koerselman J. Erkens J.A. Lammers J.W. Herings R.M. (2007) Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir Med 101: 1398–1405.
7. Calverley P.M. Boonsawat W. Cseke Z. Zhong N. Peterson S. Olsson H. (2003a) Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 22: 912–919. Erratum in: Eur Respir J 2004; 24: 1075.
8. Calverley P.M. Lee A. Towse L. van Noord J. Witek T.J. Kelsen S. (2003b) Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 58: 855–860.
9. Casaburi R. Briggs D.D. Jr Donohue J.F. Serby C.W. Menjoge S.S. Witek T.J. Jr (2000) The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. Chest 118: 1294–1302.
10. Casaburi R. Mahler D.A. Jones P.W. Wanner A. San P.G. ZuWallack R.L. (2002) A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19: 217–224.
11. Cazzola M. MacNee W. Martinez F.J. Rabe K.F. Franciosi L.G. Barnes P.J. (2008) Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 31: 416–469.
12. Cooper C.B. (2006) The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med 119(Suppl. 1): 21–31.
13. Dahl R. Chung K.F. Buhl R. Magnussen H. Nonikov V. Jack D. INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators (2010) Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 65: 473–479.
14. Dahl R. Greefhorst L.A. Nowak D. Nonikov V. Byrne A.M. Thomson M.H. (2001) Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164: 778–784.
15. Donohue J.F. Fogarty C. Lötvall J. Mahler D.A. Worth H. Yorgancioglu A. for the INHANCE Study Investigators (2010) Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 182: 155–162.
16. Donohue J.F. van Noord J.A. Bateman E.D. Langley S.J. Lee A. Witek T.J. (2002) A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 122: 47–55.
17. Feldman G. Siler T. Prasad N. Jack D. Piggot S. Owen R. (2010) Efficacy and safety of indacaterol 150 mcg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 10: 11–11.
18. Jones P.W. Mahler D.A. Gale R. Owen R. Kramer B. (2011) Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respir Med 105: 892–899.
19. Korn S. Kerwin E. Atis S. Amos C. Owen R. Lassen C. on behalf of the INSIST study group (2011) Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: A 12-week study. Respir Med 105: 719–726.
20. Kornmann O. Dahl R. Centanni S. Dogra A. Owen R. Lassen C. (2011) Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 37: 273–279.
21. LaForce C. Aumann J. de Teresa Parreño L. Iqbal A. Young D. Owen R. on behalf of the INTEGRAL study investigators (2011) Sustained 24-hour efficacy of once daily indacaterol (300 µg) in patients with chronic obstructive pulmonary disease: A randomized, crossover study. Pulm Pharmacol Ther 24: 162–168.
22. O'Donnell D.E. Lam M. Webb K.A. (1999) Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160: 542–549.
23. O'Donnell D.E. Revill S.M. Webb K.A. (2001) Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164: 770–777.
24. O–Donnell D.E. Casaburi R. Vincken W. Puente-Maestu L. Swales J. Lawrence D. on behalf of the INABLE 1 study investigators (2011) Effect of indacaterol on exercise endurance and lung hyperinflation in COPD, Respir Med, in press.
25. Partridge M.R. Karlsson N. Small I.R. (2009) Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 25: 2043–2048.
26. Rennard S.I. Tashkin D.P. McElhattan J. Goldman M. Ramachandran S. Martin U.J. (2009) Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 69: 549–565.
27. Rossi A. Kristufek P. Levine B.E. Thomson M.H. Till D. Kottakis J. (2002) Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 121: 1058–1069.
28. Szafranski W. Cukier A. Ramirez A. Menga G. Sansores R. Nahabedian S. (2003) Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21: 74–81. Erratum in: Eur Respir J 2003; 21: 912.
29. Vogelmeier C. Ramos-Barbon D. Jack D. Piggott S. Owen R. Higgins M. INTIME study investigators (INdacaterol & TIotropium: Measuring Efficacy) (2010) Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res 11: 135–135.